Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336737 · ClinicalTrials.gov registry record · NA
SentiMag® Intraoperative Comparison in Breast Cancer
A NA study of Breast Cancer, sponsored by Endomagnetics.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 6
- Study locations
NCT02336737 is a NA study of Breast Cancer that has completed, run by Endomagnetics. The registered enrollment target is 160 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT02336737, a NA study of Breast Cancer, has completed, sponsored by Endomagnetics.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this pivotal study is to provide prospective evidence that the SentiMag®/SiennaXP® is safe and non-inferior to the current standard of care for lymph node localization in patients with breast cancer as part of a sentinel lymph node biopsy (SLNB) procedure and to summarize measures of product safety and performance.
Conditions Studied
Interventions
- DEVICE SiennaXP
- DRUG Technetium Tc99m Sulfur Colloid
- DRUG Isosulfan blue dye
Study Locations (6)
California
- University of California San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Carol Franc Buck Breast Care Center - San Francisco
Texas
- Dallas Surgical Group - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Pennsylvania
- Coordinated Health Breast Care Specialists - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02336737
The ClinicalTrials.gov registry entry for NCT02336737 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Endomagnetics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which SiennaXP is the first listed.
NCT02336737 reports 6 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02336737 about?
NCT02336737 is a clinical study titled "SentiMag® Intraoperative Comparison in Breast Cancer". The purpose of this pivotal study is to provide prospective evidence that the SentiMag®/SiennaXP® is safe and non-inferior to the current standard of care for lymph node localization in patients with breast cancer as part of a sentinel lymph node biopsy (SLNB) procedure and to summarize measures of ...
What is the current status of trial NCT02336737?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2015-01. Estimated completion is 2015-12.
What conditions does trial NCT02336737 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02336737?
The interventions under investigation include: SiennaXP (DEVICE), Technetium Tc99m Sulfur Colloid (DRUG), Isosulfan blue dye (DRUG).
Who is sponsoring clinical trial NCT02336737?
This trial is sponsored by Endomagnetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02336737 being conducted?
This trial has 6 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.